KYMRIAH (Novartis Pharmaceuticals Corporation)


Welcome to the PulseAid listing for the KYMRIAH drug offered from Novartis Pharmaceuticals Corporation. This pharmaceutical is classified as a CELLULAR THERAPY. Below, you can view the details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same CELLULAR THERAPY drug type category.

LABELER NAME / MANUFACTURER: Novartis Pharmaceuticals Corporation
NON-PROPRIETARY NAME: tisagenlecleucel
SUBSTANCE NAME: TISAGENLECLEUCEL
TYPE: CELLULAR THERAPY
PHARMA CLASS:
ROUTE: INTRAVENOUS
DOSAGE FORM: INJECTION, SUSPENSION
MARKETING CATEGORY NAME: BLA
START MARKETING DATE: 2017-08-30
END MARKETING DATE: 0000-00-00


KYMRIAH CELLULAR THERAPY Details:

Item DescriptionKYMRIAH from Novartis Pharmaceuticals Corporation
LABELER NAME: Novartis Pharmaceuticals Corporation
DEA SCHEDULE:
ACTIVE STRENGTH: 2000000(1-Jan)
START MARKETING DATE: 2017-08-30
END MARKETING DATE: 0000-00-00
PRODUCT ID: 0078-0846_22dc1c28-0cf5-4290-b499-eb5391a232c2
PRODUCT NDC: 0078-0846
APPLICATION NUMBER: BLA125646

Other TISAGENLECLEUCEL Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Novartis Pharmaceuticals CorporationKYMRIAH